OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Operating Income
Profit from core operations after operating expenses, before interest and taxes.
OKYO Pharma LimitedNASDAQ: OKYO
Operating Income · Q2 FY2026 · quarter ended Sep 2025
Operating income remains negative
Q2 FY2026 operating income was -$2.79M, compared with -$3.01M a year earlier.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Mar 2026, a step up from the +54.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2025
- -$2.79M— QoQ
- Last fiscal yearMar 2025
- -$7.19M+54.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.2% | — | — |
| 1 year | +54.2% | +100.0% | +45.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (7.19M) USD
- Year-over-year change
- +54.2%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | (7.19M) | +54.2% |
| FY2024 | 2024-03-31 | (15.69M) | -19.9% |
| FY2023 | 2023-03-31 | (13.09M) | -110.0% |
| FY2022 | 2022-03-31 | (6.23M) | -50.7% |
| FY2021 | 2021-03-31 | (4.13M) | — |
Operating Income vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's FY2025 operating income of -$7.19M is the 2nd highest of the 10 companies compared; the peer median is -$36.08M.
- Its year-over-year change of +54.2% is the 2nd highest of 10, against a peer median of +25.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$2.32M | +83.8% | — | 12.6% | |
| FY2025 | -$7.19M | +54.2% | — | — | |
| LTM Mar 2026 | -$20.82M | +25.5% | — | 15535.1% | |
| FY2025 | -$21.28M | -34.8% | — | — | |
| LTM Mar 2026 | -$21.99M | -13.1% | — | 277.0% | |
| LTM Mar 2026 | -$36.08M | -65.8% | — | — | |
| LTM Mar 2026 | -$63.66M | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$119.21M | +49.3% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$122.7M | -94.3% | — | — |
| LTM Mar 2026 | -$145.04M | +31.6% | — | — | |
| Peer median (excluding OKYO) | -$36.08M | +25.5% | — | 158.8% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K |
| Gross Profit | (13.09K) | (2.42K) | (3.8K) | (3.87K) | (2.56K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M |
| Selling, General & Admin | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M |
| Operating Expenses | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M |
| Depreciation & Amortization | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| EBITDA | (3.35M) | (6.22M) | (13.18M) | (15.75M) | (7.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.13M) | (6.23M) | (13.09M) | (15.69M) | (7.19M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 5.47K |
| Interest Expense | 1.12K | 0 | 96.69K | 1.05M | 883.65K |
| Other Income / Expenses | 754.85K | 13.58K | (196.62K) | (1.11M) | (781.2K) |
| Income Before Tax | (3.38M) | (6.22M) | (13.28M) | (16.8M) | (7.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (24.99K) | (787K) | (12.2K) | 22.42K | (3.26M) |
| Net Income | (3.35M) | (5.43M) | (13.27M) | (16.83M) | (4.71M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| EPS (Diluted) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| Weighted Avg Shares | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Weighted Avg Shares (Diluted) | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.